Anbio Rolls Out Revolutionary “Point of Care” Innovations in Europe

0
166

Anbio Biotechnology is advancing into the European healthcare landscape with its leading product, the AF-100 C, a pioneering compact fluorescent immunoassay analyser poised to reshape point-of-care diagnostics. Furnished with over 70 assays, the AF-100 C seeks to augment the capabilities of EU healthcare providers, thereby enhancing patient treatment and predictive outcomes.

In its quest to expand its reach within the European Union, Anbio Biotechnology (Anbio), a key figure in the global in vitro diagnostics arena, is thrilled to unveil its extensive “Point of Care” product suite in the EU. This initiative represents a significant leap for Anbio, paving the way for new collaborative opportunities with EU distributors and healthcare entities, and underscoring the company’s commitment to equipping the EU market with top-tier diagnostic solutions.

Anbio has earned acclaim not just as a supplier of Covid testing kits but as a broad-based manufacturer and innovator of a vast range of diagnostic instruments. “Our mission is to revolutionize diagnostics by offering tailored and accessible solutions, including laboratory, wellness, at-home, and point-of-care diagnostics. We are committed to affordability and continuous innovation in life sciences that serve to advance human heath,” Michael Lau, CEO of Anbio, declared.

Advanced Analyzer Offers Access to Over 70 Crucial Tests

Central to Anbio’s introduction in the EU is the AF-100 C analyzer, a leading-edge, single-channel, portable, rechargeable compact fluorescent Immunoassay (FIA) analyzer. This formidable apparatus, along with its over 70 CE-certified assays for a wide range of analytes such as markers for inflammation, diabetes, cancer, hormones, enzymes, and infectious diseases, aims to revolutionise the clinical diagnostics field in the EU.

“The Anbio AF-100 C is a game-changer for clinical diagnostics, supplying healthcare providers with a cost-effective, comprehensive, and reliable solution for rapid point-of-care testing,” Lau emphasized. The AF-100 C, compact yet high-performing, is adaptable for a variety of medical settings, from private medical facilities to accident and emergency departments. Its user-friendly design and long-lasting battery, enabling up to 8 hours of continuous operation, ensure that healthcare personnel can deliver improved patient care efficiently and accurately.

Accelerated and Precise Diagnostics Contribute to Enhanced Health Outcomes

The extensive FIA array by Anbio, capable of providing fast outcomes within 3 to 15 minutes, signifies a notable advancement in the field of diagnostic technologies. Equipped with reagents that utilise RFID chip technology for enhanced accuracy and stable at room temperature for two years, Anbio is poised to satisfy the pressing requirements of the European healthcare industry.

As Anbio Biotechnology marks its presence in the EU marketplace, it invites distributors and medical professionals to explore its novel diagnostic solutions. Committed to bettering patient care through cost-effective, precise, and reliable diagnostics, Anbio is keen to establish partnerships with healthcare practitioners across the EU.

LEAVE A REPLY

Please enter your comment!
Please enter your name here